Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Relying On Pedigree Info To Authorize Use Of Imported Flu Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is relying on confirmed lot numbers and pedigree information to authorize the use of Sanofi-Aventis' Fluzone purchased directly from European distributors by state and local governments

You may also be interested in...



GSK Flu Vaccine To Be Available In U.S. With Informed Consent

Patients using GSK's Fluarix under IND will need to complete an informed consent form. HHS is immediately purchasing 1.2 mil doses of the influenza vaccine, with an option to procure up to 2.8 mil. additional doses.

Excess Foreign Flu Vaccine Supply Could Add 6 Mil. Doses To U.S.

FDA hopes that some or all of the excess foreign flu vaccine will be available for U.S. use by year-end, FDA Acting Commissioner Crawford tells Senate subcommittee. FDA should finish reviewing 750,000 doses of foreign vaccine purchased through distribution channels by cities and states in two to three weeks, Crawford says.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel